Why the study?
Does adriamycin improve tumor response in children with solid tumors resistant to conventional chemotherapy?
Does adriamycin improve tumor response in children with solid tumors resistant to conventional chemotherapy?
Adriamycin showed a 36% overall response rate in children with refractory solid tumors, though it was associated with toxicities including ST-segment changes.
May support activity in refractory pediatric tumors with cardiac monitoring needed; leaves open randomized confirmation of benefit.
Ninety-eight children with solid tumors resistant to conventional chemotherapy received adriamycin 90 mg/m2, either as a single intravenous injection or in 6 divided doses administered every 6 hours. Of the 88 evaluable children, 6 (7%) achieved a complete response and 26 (29%) achieved a partial response. Tumors which demonstrated significant response rates were: neuroblastoma (9/18), Wilms' tumor (7/13), rhabdomyosarcoma (4/11), and lymphoma (4/8). The toxicities observed with this regimen included: alopecia, leukopenia, thrombocytopenia, nausea, vomiting, stomatitis, febrile episodes, and ST-segment changes.
No takes yet. Share an insight, caveat, or question.
Ragab et al. (1975) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: